Asian Pacific Journal of Cancer Prevention

  • 제13권10호
  • /
  • Pages.4935-4938
  • /
  • 2012
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Fusion Between TMPRSS2 and ETS Family Members (ERG, ETV1, ETV4) in Prostate Cancers from Northern China

  • Wang, Jian-Jiang (Department of Urology, Beijing Tongren Hospital, Capital Medical University) ;
  • Liu, Yue-Xin (Department of Urology, Beijing Tongren Hospital, Capital Medical University) ;
  • Wang, Wei (Department of Urology, Beijing Tongren Hospital, Capital Medical University) ;
  • Yan, Wei (Department of Urology, Beijing Tongren Hospital, Capital Medical University) ;
  • Zheng, Yu-Peng (Department of Urology, Beijing Tongren Hospital, Capital Medical University) ;
  • Qiao, Lu-Dong (Department of Urology, Beijing Tongren Hospital, Capital Medical University) ;
  • Liu, Dan (Department of Urology, Beijing Tongren Hospital, Capital Medical University) ;
  • Chen, Shan (Department of Urology, Beijing Tongren Hospital, Capital Medical University)
  • 발행 : 2012.10.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

In this study we evaluated the frequency of fusion between TMPRSS2 and ETS family members (ERG, ETV1, ETV4) in prostate cancers in patients from northern China in order to explore differences in fusion rates among regions in northern and southern China, other parts of Asia, Europe, and North America. We examined 100 prostate cancer patients, diagnosed by means of prostate biopsy; fluorescence in situ hybridization (FISH) was used to detect the expression of TMPRSS2, ERG, ETV1 and ETV4 in cancer tissue. Differences in gene fusion rates among different ethnics groups were also analyzed. Of the 100 prostate cancer patients, 55 (55%) had the fusion gene. Among the patients with the fusion gene, 46 (83.6%) patients had the TMPRSS2:ERG fusion product, 8 (14.8%) patients had TMPRSS2:ETV1 fusion, 1 (1.6%) patient had TMPRSS2:ETV4.

키워드

참고문헌

  1. Darnel AD, Lafargue CJ, Vollmer RT, Corcos J, Bismar TA (2009). TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer Biol Ther, 8, 125-30. https://doi.org/10.4161/cbt.8.2.7134
  2. Huang L, Schauer IG, Zhang J, et al (2011). The oncogenic gene fusion TMPRSS2: ERG is not a diagnostic or prognostic marker for ovarian cancer. Int J Clin Exp Pathol, 4, 644-50.
  3. Lee K, Chae JY, Kwak C, Ku JH, Moon KC(2010). TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients. Urology, 76, 1267-8.
  4. Mao X, Yu Y,Boyd LK, et al (2010). Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res, 70, 5207-12. https://doi.org/10.1158/0008-5472.CAN-09-4074
  5. Rubio-Briones J, Fernandez-Serra A, Calatrava A, et al (2010). Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. J Urol, 183, 2054-61. https://doi.org/10.1016/j.juro.2009.12.096
  6. Song FJ, Zhang BL, He M, et al (2010). Trend analysis of the incidence of prostate cancer in Tianjin between 1981 and 2004. Zhonghua Yi Xue Za Zhi, 90, 2811-4.
  7. Sun QP, Li LY,Chen Z, et al (2010). Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study. J Mol Diag, 12, 718-24. https://doi.org/10.2353/jmoldx.2010.100002
  8. Sun YH (2004). Research on prostate cancer in China. Chin J Urol, 25, 77-80.
  9. Takai N, Miyazaki T, Fujisawa K, Nasu K, Miyakawa I (2000). Expression of c-Ets1 is associated with malignant potential in endometrial carcinoma. Cancer, 89, 2059-67. https://doi.org/10.1002/1097-0142(20001115)89:10<2059::AID-CNCR5>3.0.CO;2-3
  10. Tomlins SA, Mehra R,Rhodes DR, et al (2006). TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res, 66, 3396-400. https://doi.org/10.1158/0008-5472.CAN-06-0168
  11. Tomlins SA, Rhodes DR,Perner S, et al (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 310, 644-8. https://doi.org/10.1126/science.1117679
  12. Weir HK, Thun MJ, Hankey BF, et al (2003). Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst, 95, 1276-99. https://doi.org/10.1093/jnci/djg040

피인용 문헌

  1. TMPRSS2:ETS Fusions and Clinicopathologic Characteristics of Prostate Cancer Patients from Eastern China vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3099
  2. TMPRSS2-ERG gene fusion in prostate cancer pp.18047521, 2014, https://doi.org/10.5507/bp.2014.065
  3. Comprehensive assessment for novel prostate cancer markers in the prostate-specific antigen era: Focusing on Asians and Asian countries vol.22, pp.4, 2015, https://doi.org/10.1111/iju.12701
  4. Relative mRNA expression of prostate-derived E-twenty-six factor and E-twenty-six variant 4 transcription factors, and of uridine phosphorylase-1 and thymidine phosphorylase enzymes, in benign and malignant prostatic tissue pp.1792-1082, 2015, https://doi.org/10.3892/ol.2015.3093
  5. ERG expression in prostate cancer: biological relevance and clinical implication vol.142, pp.8, 2016, https://doi.org/10.1007/s00432-015-2096-x
  6. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer vol.37, pp.9, 2016, https://doi.org/10.1007/s13277-016-5116-9